Madrigal Pharma (MDGL): Price to Sales

Madrigal Pharmaceuticals (MDGL) management adheres to basic eco-standards, focusing on laboratory tests. The P/S multiple visualizes the results of this strategy, where 6.90 records a new level. The business relies on external contract manufacturing organizations, creating a dependency on logistics. Meanwhile, growing competition in steatohepatitis therapy threatens future drug price reductions.

Madrigal Pharmaceuticals, Inc. - MDGL P/S Multiple (period 08/09/2024 - 11/14/2026)

Metric breakdowns and analytics for madrigalpharma.com (MDGL)

- current price and projected stock value:

Price Chart Madrigal Pharmaceuticals Inc|MDGL - Price Target Chart

- stock exchange capitalization data:

Market Value Madrigal Pharmaceuticals|MDGL - Total Company Value

- shareholders' equity book value data:

Net Assets per Single Share Madrigal Pharmaceuticals|MDGL - Book Capitalization|Market Capitalization to Book Value madrigalpharma.com|MDGL - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

MDGL - Company Net Income|Expected Net Income Madrigal Pharmaceuticals|MDGL - P/E Multiple|Market Cap to Projected Earnings Madrigal Pharma|MDGL - PEG Multiple|Enterprise Value to EBITDA Multiple Madrigal Corp|MDGL - Operating profit EBITDA|Net earnings per share (EPS TTM) Madrigal Pharmaceuticals|MDGL - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months madrigalpharma.com|MDGL - Net earnings per share growth this year|Expected earnings per share trend next year Madrigal Pharmaceuticals

- issuer revenue and sales details:

MDGL - Company Revenue|Company Expected Revenue Madrigal Pharmaceuticals, Inc.|MDGL - P/S Multiple|Forward Price to Sales Madrigal Corp

Fundamental company analysis:MDGL (Madrigal Pharmaceuticals, Inc.)

Core merchandise of Madrigal Pharmaceuticals

The integration of ESG standards and biotechnology ethics into the drug development process at Madrigal Pharmaceuticals (MDGL) directly impacts long-term capitalization and asset value. By analyzing the P/S time series, an investor assesses the price-to-sales ratio, which enables the rapid identification of an overbought asset or a market capitulation phase, thereby minimizing the risk of overpaying for the business when accounting for hidden costs.

Competing companies